Crestline Management LP Grows Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Crestline Management LP raised its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 114.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 295,354 shares of the biopharmaceutical company's stock after acquiring an additional 157,366 shares during the quarter. Crestline Management LP owned approximately 0.45% of Celldex Therapeutics worth $7,464,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC lifted its position in shares of Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 878 shares during the last quarter. Headlands Technologies LLC purchased a new stake in Celldex Therapeutics during the 4th quarter worth about $81,000. KBC Group NV boosted its position in shares of Celldex Therapeutics by 79.1% during the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after acquiring an additional 1,647 shares in the last quarter. AlphaQuest LLC increased its holdings in shares of Celldex Therapeutics by 171.0% in the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock valued at $108,000 after acquiring an additional 2,705 shares during the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Celldex Therapeutics during the 4th quarter worth about $121,000.

Celldex Therapeutics Trading Down 1.8 %

NASDAQ:CLDX opened at $20.29 on Tuesday. The firm has a market cap of $1.35 billion, a P/E ratio of -7.89 and a beta of 1.39. The stock's 50 day simple moving average is $19.09 and its 200-day simple moving average is $23.07. Celldex Therapeutics, Inc. has a 12-month low of $14.40 and a 12-month high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.02. The business had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. Research analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Canaccord Genuity Group began coverage on Celldex Therapeutics in a report on Monday, April 28th. They issued a "buy" rating and a $64.00 price target for the company. UBS Group assumed coverage on shares of Celldex Therapeutics in a research note on Thursday, February 13th. They set a "buy" rating and a $44.00 price target on the stock. Morgan Stanley initiated coverage on shares of Celldex Therapeutics in a research note on Thursday, March 20th. They issued an "overweight" rating and a $46.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Friday, February 28th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $55.30.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.